Freenome is a biotechnology company that focuses on developing accurate, accessible, and non-invasive disease screening products. Since its founding in 2014, their clear vision has been to detect cancer and other diseases at their most manageable stages. They’re not afraid of tackling the hard challenges, choosing to take on cancer head-on.
Headquartered in South San Francisco, Freenome is at the forefront of liquid biopsy technology. Instead of invasive tissue biopsies, they’re developing a simple blood test. This test aims to detect early-stage cancer and other diseases by analyzing specific markers in the blood. By catching diseases early, Freenome hopes to make treatments more effective and improve patient outcomes.
Freenome’s comprehensive multiomics platform combines genomics, proteomics, and other -omics data. This approach allows them to detect cancer using routine blood draws. By analyzing various molecular signals, they can identify patterns associated with disease. Their goal is to provide accurate and actionable insights to clinicians, empowering them to intervene early.
Freenome’s values guide their work. They strive for greatness, recognizing that tackling cancer isn’t easy but is essential. Servant leadership is their style—they lead by example and help others grow. Trust, integrity, and empathy are core principles. They build products that serve diverse communities, ensuring equitable access to early disease detection.
Freenome is led by an experienced management team and supported by institutional and strategic investors. These investors bring substantial expertise in oncology, diagnostics, and operations. With their backing, Freenome continues to push the boundaries of early cancer detection, making a meaningful impact on patients’ lives.
